Blade Air Mobility Inc SEC Filings

Strata Critical Medical (SRTA) reported an insider transaction: Co‑CEO and General Counsel Melissa M. Tomkiel exercised stock options (code M) for 55,555 Class A shares at $0.18 on 10/10/2025.

Following the transaction, she beneficially owned 1,214,816 shares directly, and held 360,294 stock options outstanding. The option grant was originally exercisable from 05/07/2021 and expires 07/28/2030.

Strata Critical Medical, Inc. completed the acquisition of Keystone Perfusion Services, LLC on September 16, 2025. The buyer paid a base Purchase Price of $124 million (subject to adjustment), with payment structured eighty percent in cash and twenty percent in Strata common stock, plus up to $23 million of contingent consideration tied to performance over the next 12, 24 and 36 months.

The Purchase Price can be adjusted downward or upward by up to $12.4 million based on Keystone's 2025 adjusted EBITDA relative to specified thresholds. At Closing, after adjustments and expenses, Seller received roughly 88% cash and 12% stock. Strata issued 3,434,607 shares in reliance on exemptions from registration and obtained representation and warranty insurance as primary recourse for certain breaches. The filing includes a standard cautionary note on forward-looking statements and lists customary surviving reps, warranties and covenants.

Robert S. Wiesenthal, a director of Strata Critical Medical, Inc. (ticker: SRTA), reported a grant of 40,607 restricted stock units (RSUs) on 08/29/2025 that will be settled in common stock upon vesting. The RSUs are valued at $0 in the filing and 100% of these RSUs vest on the date of the company's 2026 Annual Meeting of Stockholders. The filing states the reporting person beneficially owns 5,275,662 shares following the reported transaction as direct ownership. The filing also discloses that, effective September 2, 2025, the issuer amended the terms of previously granted unvested RSUs totaling 886,886 and 33,591 units to add an additional performance-related vesting condition, and those units are no longer included in the beneficial ownership total until the performance condition is met. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Wiesenthal.

Amir Cohen, Chief Accounting Officer and director of Strata Critical Medical, Inc. (SRTA), reported a grant of 11,844 fully vested restricted stock units (RSUs) on 08/29/2025. The RSUs vest and will be settled in shares of the issuer's Class A common stock at no cash price ($0). Following this transaction, Mr. Cohen beneficially owns 103,760 shares. The RSU grant is effective upon completion of the issuer's previously disclosed sale of its Passenger business to Joby Aero, Inc. under an Equity Purchase Agreement dated August 1, 2025. The Form 4 was signed by attorney-in-fact Melissa M. Tomkiel on 09/03/2025.

Andrew Lauck, a director of Strata Critical Medical, Inc. (ticker: SRTA), was granted 11,844 fully vested Restricted Stock Units (RSUs) on 08/29/2025. The filing states these RSUs will be settled in shares of the issuer's common stock and are effective upon completion of the issuer's previously announced sale of its Passenger business to Joby Aero, Inc., under the Equity Purchase Agreement dated August 1, 2025. Following this transaction, the reporting person beneficially owns 130,642 shares of Class A common stock. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/03/2025.

Strata Critical Medical, Inc. filed an 8-K reporting several corporate governance changes, including a name change and the appointment of Co-Chief Executive Officers. The filing states the board will require independent members to elect a Lead Independent Director whenever the chairman is not independent or previously served as an officer, and describes the powers and duties of that role. The company amended bylaws to limit the number of stockholder-nominated director candidates at a meeting to the number of directors up for election and to revise procedural mechanics and disclosure obligations for nominations, proposals, and proxy solicitations. Additional bylaw changes address adjournments and align provisions with the Delaware General Corporation Law, plus clarifying and technical edits. The filing is dated August 29, 2025 and is signed by William A. Heyburn as Co-Chief Executive Officer and Chief Financial Officer.

Scott M. Wunsch, an officer and director of Blade Air Mobility, Inc. (BLDE), reported a grant of 22,365 Restricted Stock Units (RSUs) on 08/14/2025. The RSUs are to be settled in shares of the company’s Class A common stock at $0 per share and will vest in full on December 8, 2025, subject to Wunsch's continued service. Following the reported grant, Wunsch beneficially owns 304,021 shares directly and an additional 382,987 shares indirectly through an LLC of which he is the sole member. The filing was signed by an attorney-in-fact on behalf of Wunsch on 08/18/2025.

Third Point LLC and Daniel S. Loeb report beneficial ownership of 5,000,000 shares of Blade Air Mobility, Inc., equal to 6.12% of the company's common stock. The percentage is calculated using the issuer's reported 81,695,605 shares outstanding as of July 29, 2025. Both reporting persons state shared voting and shared dispositive power for the 5,000,000 shares and report no sole voting or dispositive power.

The Schedule 13G filing includes a certification that the securities were not acquired to change or influence control of the issuer, clarifying the reporting persons' stated passive intent. The disclosure is material because it exceeds the 5% reporting threshold and identifies who holds meaningful shared influence over the issuer's voting rights.